COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.
“Although most autoimmune diseases are considered to be CD4 T cell- or antibody-mediated, many respond to CD20-depleting antibodies that have limited influence on CD4 and plasma cells. This includes rituximab, oblinutuzumab and ofatumumab that are used…
Read more
